How to optimize HCV therapy in genotype 4 patients.

about

Cross reactive cellular immune response to HCV genotype 1 and 4 antigens among genotype 4 exposed subjects.Management of hepatitis C genotype 4 in the directly acting antivirals era.Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4.

P2860

Q33826033-FE26461C-84BA-47EC-95A3-16B22621A33F Q37312151-E23C25F5-6882-4283-ABAF-B9EBD0FC4E69 Q38948533-8B9EFDEF-BA61-4DA3-A279-48159BE07E17

P2860

How to optimize HCV therapy in genotype 4 patients.

Item

http://www.wikidata.org/entity/Q38071388

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

How to optimize HCV therapy in genotype 4 patients.

@en

type

Item

label

How to optimize HCV therapy in genotype 4 patients.

@en

prefLabel

How to optimize HCV therapy in genotype 4 patients.

@en

P1476

How to optimize HCV therapy in genotype 4 patients

@en

P2093

Mohamed Esmat Gamil

http://www.w3.org/2001/XMLSchema#string

P2860

Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium

High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin.

Quasispecies of genotype 4 of hepatitis C virus genomes in Saudi patients managed with interferon alfa and ribavirin therapy

Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms.

The way forward in HCV treatment--finding the right path.

Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"?

P304

41-45

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/LIV.12059

http://www.w3.org/2001/XMLSchema#string

P478

33 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256389445

http://www.w3.org/2001/XMLSchema#string

P698

23286845

http://www.w3.org/2001/XMLSchema#string

How to optimize HCV therapy in genotype 4 patients.

about

P2860

P2860

How to optimize HCV therapy in genotype 4 patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P5875

P698